Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 21, 2009 at 10:00 am Eastern

ROCKVILLE, Md.--(Business Wire)--
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold its
Annual Meeting of Stockholders on Thursday, May 21, 2009 beginning at 10:00 am
Eastern Time at the Crowne Plaza Hotel, 3 Research Court, Rockville, MD, 20850.

At the annual meeting, stockholders will consider and vote on the following
matters:

1
the election of Daniel J. Abdun-Nabi and Dr. Sue Bailey to serve as
Class III directors, each for a term of three years;
2
the approval of the company’s Amended and Restated 2006 Stock
Incentive Plan, which is proposed primarily for, among other purposes,
increasing the number of shares authorized for issuance under our 2006
Stock Incentive Plan by 3,900,000 shares and extending the term of the
plan from December 31, 2009 to December 31, 2019; and
3
the ratification of the selection by the audit committee of Ernst &
Young LLP as the company’s independent registered public accounting
firm for the fiscal year ending December 31, 2009.

Stockholders also will consider and vote on any other matters as may properly
come before the annual meeting or any adjournment or postponement thereof. The
company`s board of directors has no knowledge of any other matters which may
come before the meeting.

Stockholders of record at the close of business on March 27, 2009 are entitled
to notice of, and to vote at, the annual meeting or any adjournment or
postponement thereof.

If you plan to attend the meeting, please bring photo identification for
admission. Also, if your shares are held in the name of a broker, bank or other
nominee, please bring with you a proxy, letter or account statement (or copy
thereof) from your broker, bank or nominee confirming your ownership of Emergent
BioSolutions stock so that you can be admitted to the meeting. Also, if your
shares are held of record by a broker, bank or other nominee and you wish to
vote at the meeting, you must obtain a broker`s proxy card issued in your name.

Interested parties may listen to the Annual Meeting via conference call by
dialing either 866/314-5232 in the U.S. or 617/213-8052 outside the U.S. No
passcode is required for the live call. Interested parties may also access a
webcast of the Annual Meeting by visiting the Emergent BioSolutions website at
www.emergentbiosolutions.com.

A replay of the teleconference will be available approximately one hour
following the conclusion of the call by dialing 888/286-8010 or 617/801-6888 and
using the passcode 73054208. The replay will be available through July 28. In
addition, the webcast will be archived on the company`s website,
www.emergentbiosolutions.com, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and therapeutics that
assist the body`s immune system to prevent or treat disease. Emergent`s marketed
product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by
the U.S. Food and Drug Administration for the prevention of anthrax. Emergent`s
development pipeline includes programs focused on anthrax, botulism,
tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be
found at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements, other than
statements of historical fact, including statements regarding our strategy,
future operations, future financial position, future revenues, projected costs,
prospects, plans and objectives of management, including any potential future
securities offering, and any other statements containing the words "believes",
"expects", "anticipates", "plans", "estimates" and similar expressions, are
forward-looking statements. There are a number of important factors that could
cause the company's actual results to differ materially from those indicated by
such forward-looking statements, including the timing of, and the potential for
successful outcomes resulting from future product development efforts and our
ability to obtain additional funding from the U.S. government, our plans to
expand our manufacturing facilities and capabilities; the rate and degree of
market acceptance and clinical utility of our products; and other factors
identified in the company's quarterly report on Form 10-Q for the period ended
March 31, 2009 and subsequent reports filed with the SEC. The company disclaims
any intention or obligation to update any forward-looking statements as a result
of developments occurring after the date of this press release.

Emergent BioSolutions
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com

Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Copyright Business Wire 2009